Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 3, 2008, Pages 138-145

  Hitsumoto, Takashi ^a   Takahashi, Mao ^a   Iizuka, Takuo ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypertension; Peroxisome proliferator activated receptor ; Preheparin serum lipoprotein lipase mass; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; HEPARIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

AGED; ARTICLE; BLOOD; DRUG ANTAGONISM; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; FEMALE; HEPARIN; HUMANS; HYPERTENSION; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PPAR GAMMA; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 48849086696     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E547     Document Type: Article

References (58)

1. Nilsson-Ehle P, Garfinkel AS, and Schotz MC: Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem, 1980; 49:667-693
2. Louis CS and Henry JP: Lipoprotein lipase. In: Lipases ed by Borgstrom B and Brockman HL. pp263-305, Elsevier, Amsterdam, 1984
3. Braun JE and Severson DL: Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J, 1992; 287:337-347
4. Sexena U, Klein MG, and Goldberg IJ: Transport of lipoprotein lipase across endothelial cells, Proc Natl Acad Sci USA, 1991; 88:2254-2258
5. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, and Yoshida S: Lipoprotein lipase mass and activity in severe hypertriglyceridemia, Clin Chim Acta, 1993; 216:113-123
6. Tornvall P, Olivecrona G, Karpe F, Hamsten A, and Olivecrona T: Lipoprotein lipase mass and activity in plasma and their increase after heparin injection are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15:1086-1093
7. Hitsumoto T, Ohsawa P, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, and Shirai K: Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis, Atherosclerosis, 2000; 153:391-396
8. Hitsumoto T, Yoshinaga K, Aoyagi K, Sakurai T, Kanai M, Uchi T, Noike H, Ohsawa H, Watanabe H, and Shirai K: Association between prrheparin strum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb, 2002; 9:163-169
9. Hitsumoto T, Takahashi M, Iizuka T, and Shirai K: Relationship between preheparin lipoprotein lipase mass concentration in serum and bare metal stent restenosis, J Cardiol, 2006; 48:65-73
10. Rip J, Nierman MC, Wareham NJ, Luben R, Bingham SA, Day NE, van Miert JN, Hutten BA, Kastelein JJ, Kuivenhoven JA, Khaw KT, and Bockholdt SM: Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol, 2006; 26:637-642
11. Kobayashi J: Pre-heparin lipoprotein lipase mass, J Athtroscler Thromb, 2004; 11:1-5
12. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, Otsuka M, Ito Y, and Shirai K: Atorvastatin and pravastatin eleva ted pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb, 2004; 11:341-347
13. Sasaki H, Kanai S, Oyama T, Miyashita Y, and Shirai K: Usefulness of preheparin lipoprottin lipase mass as a parameter for predicting the efficacy of colestimide. J Atheroscler Thromb, 2005; 12:218-224
14. Sasaki H, Kanai S, Oyama T, Miyashita Y, Yamamura S, and Shirai K: Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2006; 13:149-157
15. Saiki A, Ohira M, Endo K., Koide N, Oyama T, Murano T, Miyashita. Y, and Shirai K: The angiotensin II receptor antagonist valsartan enhances lipoprottin lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract, 2006; 74:242-248
16. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, and Stamler J: Blood pressure, stroke, and coronary heart disease, Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990; 335:765-774
17. Tight blood pressure control and risk of macrovsascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group. BMJ, 1998; 317:703-713
18. Lewington S, Clarke R, Qizilbash N, Peto R, and Collins R: Prospective Studies Collaboration, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360: 1903-1913
19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T. Laragh J, McInnes GT Mitchell L, Plat E, Sch ork A, Smith B, and Zanchetti A: VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004; 363:2022-2031
20. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV. Saad MF, Savage P, and Bergman R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators, Circulation, 1996; 93:1809-1817
21. Psyrogiannis AJ, Alexopoulos DK, Kyriazopoulou VE, and Vagenakis AG: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in patients with coronary artery disease independent of obesity. Angiology. 1998; 49:607-612
22. Matsumoto K, Kizaki Y, Fukae S, Tomihira M, Sera Y, Ueki Y, Tom inaga T. and Miyake & Insulin resistance and ccronary risk factors in Japanese type 2 diabetic patients with definite coronary artery disease. Diabetes Res Clin Pract, 2001; 51:181-186
23. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, and Skene A: PROactive Study Group, The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care, 2004; 27:1647-1653
24. Staniloae C, Mandadi V, Kurian D, Coppola J, Bernaski E, El-Khally Z, Morlote M, Pinassi E, and Ambrose J: Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology, 2007; 108:164-169
25. Sourij H, Zweiker R, and Wascher TC: Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control insubjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care, 2006; 29:1039-1045
26. Schoonjans K. Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M. Deeb S. Staels B, and Auwerx J: PPA-Ralpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 1996; 15:5336-5348
27. Kageyama H, Hirano T, Okada K, Ebara T, kageyama A, Murakami T, Shioda S, and Adachi M. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Biochem Biophys Res Commun, 2003; 305:22-27
28. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T. Watanabe H, and Miyashita Y: The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. J Diabetes Res Clin Pr, 1999; 46:35-41
29. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P. Pravcriec M, Qi N, Wang J, Avery MA., and Kurtz TW, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004; 43:993-1002
30. Schupp M, Janke J, Clasen R, Unger T. and Kintscher U: Angiotensin type 1 receptor blockers induce pcroxisome proliferatot-activated receptor-gamma activity. Circulation 2004; 109:2054-2057
31. Council on Cardiovascular Surgery, American Heart Association. Report of the committee for grading of coronary art'ery disease: a reporting system on patients evaluated for coronary artery disease. Circulation, 1975; 51:7-38
32. Fridtwald WT, Levy RI, and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499-502
33. Matthews DR, Hosker JF, Rudenski AS, Naylor BA, Treachtr DF, and Turner RC: Homeostasi s model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412-419
34. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, Arai T, Kotani K, Funahashi T, Yamashita. S, and Matsuzawa Y: Abdominal fat: standardized technique for measurement at CT. Radiology, 1999; 211:283-286
35. Hirano T, Nishioka F, and Murakami T: Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: Comparison with postheparin plasma. Metabolism, 2004; 53;526-531
36. Kobayashi J, Nohara A, Kawashiri MA, Inazu A, Koizumi J, Nakajima K, and Mabuchi H: Serum lipoprotein lipase mass: clinical significance of its measurement. Clin Chim Acta, 2007;373:7-12
37. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, and Kikkawa R: Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/ O2-imbalance in insulin-resistant rat aorta. Diabetes, 1999; 48:2437-2445
38. Kashiwagi, A, Shinozaki K, Nishio Y, Okamura T, Toda N, and Kikkawa R: Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes Res Clin Pract, 1999; 45:199-203
39. Kashiwagi A, Shinozaki K, Nishio Y, Maegawa H, Maeno Y, Kanazawa A, Kojima H, Haneda M, Hidaka H, Yasuda H, and Kikkawa R: Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol, 1999; 277:E976-E983
40. Stout RW: Insulin and atheroma. 20-yr perspective. Diabetes Care, 1990; 13:631-654
41. Pulinilkunnil T, Qi D, Ghosh S, Cheung C, Yip P, Varghese J, Abrahani A, Brownsey R, and Rodrigues B: Circulating triglyceride lipolysis facilitates lipoprotein lipase translocation from cardiomyocyte to myocardial endothelial lining. Cardiovasc Res, 2003; 59:788-797
42. Renier G and Lambert A: Lipoprotein lipase synergizes with interferon gamma to induce macrophage nitric oxide synthetase mRNA expression and nitric oxide production. Arterioscler Thromb Vasc Biol, 1995; 15:392-399
43. Hitsumoto T, Yoshinaga K, Noike H, Kanai M, and Shirai K: Clinical significance of preheparin serum lipoprotein lipase mass in coronary vasospasm. Jpn Circ J, 2001; 65:539-544
44. Mori Y, Itoh Y, and Tajima N: Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther, 2007; 24:146-153
45. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, and Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12 month study. Hypertens Res, 2004; 27:457-464
46. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, and Ozaki N: Replacement of valsartan and candesartan by hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care, 2005; 28:757-758
47. Negro R, Formoso G, and Hassan H: The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest, 2006; 29:957-961
48. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalo-usdian S, and Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256:2835-2838
49. Gordon DJ and Rifkind BM: High-density lipoprotein: the clinical implications of recent studies. N Engl J Med, 1989; 321:1311-1316
50. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, and Itakura H; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J, 2002; 66:1087-1095
51. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, and Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988; 260:1917-1921
52. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, and Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA, 1996; 276:882-888
53. Koba S and Hirano T: Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med, 2000; 132:762
54. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, and Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004; 43:993-1002
55. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, and Saito Y: Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res, 2001; 33:412-416
56. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, and Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest, 1998; 101:1354-1361
57. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, and Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem, 2001; 276:41245-41254
58. Shimabukuro M, Tanaka H, and Shimabukuro T: Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens, 2007; 25:841-848